title: Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder.
abstract: OBJECTIVE
  To determine the adequacy of pharmacotherapy received by patients with newly-diagnosed obsessive-compulsive disorder (OCD), based on current practice guidelines.
  
  
  METHODS
  A 9 year (1997-2006) retrospective claims analysis of adults enrolled in Florida Medicaid for at least 3 continuous years was conducted to determine the percentage who received both a minimally effective duration (> 8 continuous weeks) and dose of first-line OCD pharmacotherapy during the year following their first ("index") OCD diagnosis.
  
  
  RESULTS
  Among 2,960,421 adult (> 18 years of age) enrollees, 2,921 (0.1%) were diagnosed with OCD. Among the 2,825 OCD patients without comorbid Asperger syndrome or autism, 843 had newly-diagnosed OCD and at least 12 months of follow-up data after their index diagnosis. Among these 843 patients, 588 (69.7%) received first-line OCD pharmacotherapy but only 323 (38.3%) received a minimally effective pharmacotherapy trial in the year following their index diagnosis.
  
  
  CONCLUSIONS
  Among clinically-diagnosed persons with OCD (<10% of those with the disorder), a minority of newly-diagnosed patients receive a minimally effective pharmacotherapy trial consistent with current standards of care. Reasons such as limited patient adherence and/or physician awareness of guidelines must be identified and redressed to ameliorate the patient, healthcare system, and economic burdens associated with OCD.
authors.affiliation: BioMedEcon LLC, Moss Beach, CA, USA. CHankin@biomedecon.com
authors.forename: Cheryl S
authors.initials: CS
authors.lastname: Hankin
authors.forename: Lorrin M
authors.initials: LM
authors.lastname: Koran
authors.forename: Amy
authors.initials: A
authors.lastname: Bronstone
authors.forename: Donald W
authors.initials: DW
authors.lastname: Black
authors.forename: David V
authors.initials: DV
authors.lastname: Sheehan
authors.forename: Eric
authors.initials: E
authors.lastname: Hollander
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Dunn
authors.forename: Larry
authors.initials: L
authors.lastname: Culpepper
authors.forename: John
authors.initials: J
authors.lastname: Knispel
authors.forename: Darin D
authors.initials: DD
authors.lastname: Dougherty
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D016208:Databases, Factual / Q000706:statistics & numerical data; D005260:Female; D005431:Florida / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis* / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D010349:Patient Compliance / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents